NASDAQ · Biotechnology

NGM Biopharmaceuticals, Inc. (NGM) Stock

$1.54 -1.28% NASDAQ: NGM Healthcare

NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer.

Valuation

MetricValue
Price$1.54
Market Cap$128.53M
P/E Ratio-0.89
P/B Ratio0.85
P/S Ratio29.10
EPS (TTM)$-1.73
52-Week High$4.69
52-Week Low$0.60
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-69.76%
ROA-84.31%
ROCE-98.49%
Gross Margin49.72%
Operating Margin-3675.00%
Net Margin-3550.00%
Debt/Equity0.00
Current Ratio7.79

Annual Financials (USD)

Metric20192020202120222023
Revenue$104.0M$87.0M$78.0M$55.0M$4.0M
Operating Profit$-49.0M$-104.0M$-121.0M$-166.0M$-147.0M
Net Profit$-28.0M$-94.0M$-114.0M$-159.0M$-142.0M
EPS$-0.57$-1.37$-1.48$-1.99$-1.73
Op Margin-47.6%-118.8%-155.0%-300.4%-3317.8%

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$380.0M$329.0M$402.0M$307.0M$169.0M
Total Liabilities$50.0M$49.0M$67.0M$48.0M$20.0M
Cash$246.0M$147.0M$152.0M$73.0M$59.0M
Borrowings$0$0$10.0M$5.0M$0

Latest News

NuGen Medical Devices Files Two More Patent Applications MT Newswires · Jul 28, 2026 NuGen Adds to Core Patent Portfolio for Future Needle-Free Platforms TMX Newsfile · Jul 27, 2026 NuGen Medical Devices Files Patent for Dual Spring Technology Enhancing Needle-Free Injection Performance TMX Newsfile · May 28, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-41.0M$-83.0M$-73.0M$-144.0M$-132.0M
Investing Cash Flow$45.0M$-53.0M$-73.0M$12.0M$113.0M
Financing Cash Flow$181.0M$36.0M$150.0M$54.0M$2.0M
Net Cash Flow$188.0M$-99.0M$5.0M$-76.0M$-15.0M
Free Cash Flow$-45.0M$-85.0M$-75.0M$-146.0M$-133.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.06
EV / EBITDA-0.48
FCF Yield-103.83%
Quick Ratio7.79
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, and licensing agreements with Merck Sharp & Dohme Corp. A separate collaboration with Merck & Co., Inc. is dedicated primarily to creating new treatments for pressing unmet patient needs in retinal and cardiovascular-metabolic (CVM) diseases, such as heart failure. Established in 2007, NGM Biopharmaceuticals, Inc. maintains its corporate headquarters in South San Francisco, California.

NGM Biopharmaceuticals, Inc. is headquartered in US.

NGM Biopharmaceuticals, Inc. (NGM) stock trades at $1.54 with a market capitalization of $128.53M. The stock is valued at a price-to-earnings (P/E) ratio of -0.89, price-to-book of 0.85, price-to-sales of 29.10. Over the past 52 weeks the stock has ranged between $0.60 and $4.69, and currently trades 67.2% below its 52-week high.

On profitability, NGM Biopharmaceuticals, Inc. generates a return on equity (ROE) of -69.76%, return on capital employed of -98.49%, an operating margin of -3675.00%, a net profit margin of -3550.00%.

Official website: www.ngmbio.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides